Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection

Next Previous
X
Search
Trial Profile

A Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ledipasvir/sofosbuvir (Primary) ; Radalbuvir (Primary) ; Sofosbuvir (Primary) ; Velpatasvir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ELECTRON-2
  • Sponsors Gilead Sciences

    • Most Recent Events

    • 12 Nov 2015 According to media release of Gilead Sciences, results were published.
    • 12 Nov 2015 Results published in the Media Release
    • 12 Nov 2015 According to Gilead Sciences media release, U.S. Food and Drug Administration (FDA) approved Harvoni (ledipasvir/sofosbuvir) for the expanded use in patients with genotype 4, 5 and 6 chronic hepatitis C virus (HCV) infection. The supplemental new drug application sNDA approval was granted on the basis of data from this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top